Hi allFor anyone who may be interested in Imugene's partnership...

Hi all

For anyone who may be interested in Imugene's partnership with Arovella (combination therapy of OnCARlytics with Arovella's INKT CD19 DRUG - ALA-101), it is worth watching a presentation by Arovella which came out 3 weeks ago.

For a good summary of CAR-T therapy, and its limitations, watch from 2:50 to 6:05

For an explanation of Arovella's INKT therapy, and its advantages, watch from 6:05 to 8:41

If you want to learn in much more detail about INKT' and ALA-101 specifically, watch from 6:05 to 27:30

For Arovella's explanation of their partnership with IMU for combo therapy of ALA-101 with OnCARlytic, watch from 29:42 to 33:30

Imugene is also in partnership for OnCARlytics combo therapy with Celularity (their Cycart-19 drug) and with Eureka (their Artemis CD-19 drug) - now licensed out to Estrella Biopharma.

The common feature of all three partners is that each have a unique approach which potentially improves on existing CAR-T therapy.

It will be interesting to see if one of the "mainstream" - already commercialised - CAR-T therapies also partners with Imugene.

For an interesting summary of all current CAR-T players, this recent article is very useful:

https://bioinformant.com/car-t-companies-the-meteoric-rise-of-cellular-immunotherapies/

The list of around 100 companies includes many which are in early stages of development, plus other such as Gilead and Novartis which have big selling CAR-T's already approved and in use. (PS to gain access to the article you will have to enter an email address - presumably because they want to spam you with other stuff. I used an old email of mine which is no longer current or working, but that was enough to get access to the article and I won't get spammed.)

Cheers

Dave